SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

The sales for the December 2025 quarter moved down to Rs. 56877.70 millions as compared to Rs. 61807.80 millions during the year-ago period.The Net Profit of the company slipped to Rs. 7054.40 millions from Rs. 11558.00 millions, a decline of -38.97% on QoQ basis.The company reported a good operating profit of 19385.00 millions compared to 17736.50 millions of corresponding previous quarter.


(Rs. in Million)


  Quarter ended Year to Date Year ended
  202512 202412 % Var 202512 202412 % Var 202503 202403 % Var
Sales 56877.70 61807.80 -7.98 158378.40 158013.20 0.23 230033.30 202751.70 13.46
Other Income 3429.20 690.50 396.63 11905.40 3755.70 217.00 6239.70 4657.60 33.97
PBIDT 19385.00 17736.50 9.29 51897.20 40445.40 28.31 71620.50 60533.70 18.32
Interest 2441.70 2312.60 5.58 7157.90 7063.80 1.33 8932.10 7840.80 13.92
PBDT 14356.30 15423.90 -6.92 39275.90 33381.60 17.66 62688.40 50502.70 24.13
Depreciation 3385.30 3027.80 11.81 9738.60 9698.20 0.42 12382.70 16006.20 -22.64
PBT 10971.00 12396.10 -11.50 29537.30 23683.40 24.72 50305.70 34496.50 45.83
TAX 3916.60 838.10 367.32 9305.40 1363.50 582.46 7479.50 5914.70 26.46
Deferred Tax 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
PAT 7054.40 11558.00 -38.97 20231.90 22319.90 -9.35 42826.20 28581.80 49.84
Equity 2399.30 2399.30 0.00 2399.30 2399.30 0.00 2399.30 2399.30 0.00
PBIDTM(%) 34.08 28.70 18.77 32.77 25.60 28.02 31.13 29.86 4.28

Sun Pharma Inds. Share Price

1665.25 -2.75 (-0.16%)
21-Apr-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1665.25
Dr. Reddys Lab 1220.75
Cipla 1232.90
Zydus Lifesciences 928.85
Lupin 2311.75
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×